BioCentury
ARTICLE | Company News

Anaptys, Tesaro deal

March 17, 2014 7:00 AM UTC

AnaptysBio granted Tesaro exclusive, worldwide rights to mono-specific antibodies and dual reactive antibodies targeting three immune checkpoint receptors. AnaptysBio will receive $17 million up front and research funding. The companies will jointly work on preclinical development, and Tesaro will be responsible for further development and commercialization. AnaptysBio is eligible for $18 million in R&D milestones, $90 million in regulatory milestones and undisclosed sales milestones for each program, plus tiered single-digit royalties. The companies said Tesaro will develop novel monotherapy and combination- based approaches with immuno-oncology and other anti-cancer agents, but declined to disclose specific indications. ...